12.01.2020, 1019 Zeichen

Valneva: Austrian Frensch biotech company Valneva SE announced that an End Of Phase 2 (EOP2) meeting has been scheduled with the U.S. Food and Drug Administration (FDA) on February 24, 2020 for its single-shot chikungunya vaccine candidate, VLA1553. The Company plans to present its plan for Phase 3 clinical studies and licensure. VLA1553 has been awarded Fast Track designation by the FDA and may be eligible for a Priority Review Voucher. Wolfgang Bender, chief medical officer of Valneva, commented: “We are extremely pleased that the FDA has accepted our proposal for an EOP2 meeting. Subject to the outcome we may commence Phase 3 clinical trials within a few months. We are strongly committed to advancing VLA1553, currently the only chikungunya vaccine candidate in clinical development showing fully sustained titers one year after a single vaccination, through the accelerated approval.”
Valneva: weekly performance: 9.29%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (07/01/2020)

Christian Drastil: Wiener Börse Plausch

kapitalmarkt-stimme.at daily voice 92/365: Ich beantworte 5 HörerInnen-Fragen zum Aktienmarkt so gut es geht, so weit ich darf (1)

Bildnachweis

Aktien auf dem Radar:Porr, FACC, DO&CO, Agrana, Frequentis, Pierer Mobility, Lenzing, Semperit, AT&S, CA Immo, Josef Manner & Comp. AG, Palfinger, Stadlauer Malzfabrik AG, Warimpex, Addiko Bank, Flughafen Wien, Oberbank AG Stamm, Zumtobel, RHI Magnesita, Austriacard Holdings AG, Amag, OMV, Österreichische Post, Telekom Austria, Uniqa, VIG.

---